Related Experiment Video

Updated: Jan 18, 2026

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.5K

Glucagon-like peptide-1 medicines and cancer

Julian M Yabut1, Daniel J Drucker2

  • 1Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.

Nature Cancer
|January 16, 2026
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) medicines aid type 2 diabetes and obesity management by reducing weight and inflammation. These therapies may also lower cancer incidence through weight-dependent and independent pathways.

Area of Science:

  • Endocrinology
  • Oncology
  • Metabolic Diseases

Background:

  • Glucagon-like peptide-1 (GLP-1) receptor agonists are established treatments for type 2 diabetes and obesity.
  • GLP-1 medicines demonstrably reduce food intake, body weight, insulin resistance, and inflammation.
  • Emerging evidence suggests a potential role for GLP-1 medicines in cancer prevention.

Purpose of the Study:

  • To review the impact of GLP-1 medicines on cancer incidence in individuals with type 2 diabetes.
  • To examine the effects of GLP-1 receptor signaling on preclinical cancer models.
  • To elucidate the mechanisms by which GLP-1R signaling influences cancer development and progression.

Main Methods:

  • Analysis of cancer incidence data from clinical trials and patient registries.
  • Review of preclinical studies investigating GLP-1 medicine effects on cancer models.
  • Synthesis of current knowledge on direct and indirect mechanisms linking GLP-1R to tumorigenesis.

Main Results:

  • GLP-1 medicines are associated with improved outcomes in type 2 diabetes and obesity.
  • Data suggest GLP-1 medicines may suppress tumorigenesis via weight-loss-dependent and independent routes.
  • GLP-1R signaling pathways are implicated in both cancer development and progression.

Conclusions:

  • GLP-1 medicines show promise in reducing obesity-associated cancer incidence.
  • Further research into GLP-1R signaling mechanisms is warranted to fully understand its role in cancer.
  • GLP-1 receptor agonists represent a potential therapeutic strategy for cancer risk reduction.

More Related Videos

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

10.0K
Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells09:16

Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells

Published on: April 20, 2017

16.1K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
850
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
838
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
587
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
596
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K